¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü(ÄÁº¥¼ÇȦ)

±³À°ÁÖÁ¦ : 2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 02-2038-7988  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 55ºÐ

¼¼ºÎ¼ö°­·á : 20,000¿ø  

ºñ°í »çÀüµî·Ï -Àü¹®ÀÇ 20,000¿ø -Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø 10,000¿ø -ÇöÀåµî·Ï ºÒ°¡


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:10~09:25 Genetic test of prostate cancer based on clinical practice: When, How, Who? ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:25~09:40 Is PSA sufficient to screening for prostate biopsy? : PSA kinetics, New biomarker (PHI, 4K, etc.) or mpMRI ÀÌÁ¾¼ö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:40~09:55 What is the optimal technique in the era of MR-targeted biopsies and PSMA-PET/CT? ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:55~10:10 Discussion ¼ÛÇÊÇö(¿µ³²ÀÇ´ë)

ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:10~10:30 Coffee Break ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:30~10:45 Which option is considered the most effective for localized low-risk prostate cancer in 2023 : active surveillance, surgery, or radiation therapy? ½ÅÅÃÁØ(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:45~11:00 Changing evidence and guidelines for monitoring during active surveillance À¯¼ºÇö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:00~11:15 Current guidelines of focal therapy in treating prostate cancer ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:15~11:35 Discussion ÀüȲ±Õ(¼º±Õ°üÀÇ´ë)

½Ä»ç 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:35~12:35 Lunch ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:35~12:50 Real clinical advantage of neoadjuvant ADT before radical prostatectomy. ÃÖ¼¼¿µ(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:50~13:05 Treatment guidelines for cN0 and cN1 Źü½Ä(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:05~13:20 Treatment guidelines for pN0 and pN1 after radical prostatectomy ÃÖ¼¼¹Î(°æ»óÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:20~13:40 Discussion ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:40~13:55 What are the prophylactic or treatment options for voiding dysfunction following RP or RT? ¹ÚÇü±Ù(°Ç±¹ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:55~14:10 What are the prophylactic or treatment options for erectile dysfunction following RP or RT? ÇÏÀ±¼®(°æºÏÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:10~14:25 Discussion ¹ÚÀ翵(°í·ÁÀÇ´ë)

ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:25~14:45 Coffee Break ()

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:45~15:00 Guidelines of radiotherapy for distant metastases ¼­¿øÀÍ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:00~15:15 What is oligometastatic prostate cancer and how should it be treated in the era of  PSMA-PET/CT? ±èÁ¾¿í(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:15~15:30 What should be selected as the first treatment for mHSPC in actual clinical practice? Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:30~15:45 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â ´ëÇѵΰæºÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-10
´ÙÀ½±Û °­µ¿°æÈñ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 2023 Kyung Hee Knee Symposium(ÃÊ·Ï ¹ßÇ¥) : 2023-06-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
377 ¼­¿ï Á¦12ȸ ÁöµµÀü¹®ÀÇ Àü¹®ÇÐȸ(°¡Á¤ÀÇÇÐȸ) ±³À° : 2018-08-25 0 885 2018-08-15
376 ¼­¿ï Á¦13Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ ¼­¿ï°æÀÎ(°­¿ø-Á¦ÁÖ)Áöȸ : 2018-08-25 0 771 2018-08-15
375 ¼­¿ï 2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25 0 637 2018-08-15
374 ÀÎõ ´ëÇѽ½°üÀýÇÐȸ Á¦5ȸ Korea-Japan Knee Osteotomy Symposium : 2018-08-25 0 1,361 2018-08-15
373 °­¿ø 2018³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ ¿¬±¸È¸¿¬ÇÕ Á¤±âÇмú´ëȸ : 2018-08-24 0 372 2018-08-15
372 ¼­¿ï ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Ư°­ : 2018-08-23 0 309 2018-08-15
371 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ 283Â÷ ¿ù·ÊÁý´ãȸ : 2018-08-23 0 649 2018-08-15
370 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ Á¦4ȸ µÎ°æºÎ ÃÊÀ½ÆÄ ¿¬¼ö ¼¼¹Ì³ª : 2018-09-30 0 1,958 2018-08-08
369 ´ë±¸ ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ´ë±¸¡¤°æºÏ ÁöºÎȸ Á¦2Â÷ ÇмúÁý´ãȸ : 2018-09-20 0 544 2018-08-08
368 °æ³² ´ëÇѼҾưúÇÐȸ °³Á¤µÈ °¡¿Í»çÅ°º´ Áø·áÁöħ¿Ü 1°Ç : 2018-09-20 0 783 2018-08-08
367 °­¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ °­¿øÁöȸ Áý´ãȸ : 2018-09-15 0 1,168 2018-08-08
366 °æ±â ±¹¸³¾Ï¼¾ÅÍ ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ǹ®´õ½Ê°úÁ¤ : 2018-09-15 0 600 2018-08-08
365 Àü³² Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14 0 1,071 2018-08-08
364 ºÎ»ê ºÎ»ê¼Ò¾Æ°úÇÐȸ Á¤±â Çмú Áý´äȸ : 2018-09-13 0 1,518 2018-08-08
363 ´ë±¸ ´ëÇÑÄ¡¸ÅÇÐȸ ´ë±¸°æºÏÁöȸ 2018 Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-13 0 481 2018-08-08
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷